Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Celcuity Stock Quote

Celcuity (NASDAQ: CELC)

$16.94
(-1.7%)
-$0.30
Price as of April 24, 2024, 4:00 p.m. ET

Celcuity Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
CELC +78.50% -21.61% -4.75% +21%
S&P +22.56% +73.28% +11.62% +102%

Celcuity Company Info

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.